Evaluation of the Effectiveness of Prophylactic LMWH by Thromboelastography

Evaluation of the Effectiveness of Prophylactic Low Molecular Weight Heparin by Thromboelastography in Patients Who Underwent Lobectomy Due to Malignancy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06484231

Enrollment

Registered

2024-07-03

Start date

2023-07-24

Completion date

2025-08-06

Last updated

2025-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignancy

Keywords

malignancy, lobectomy, prophylaxis, thromboelastography

Brief summary

This study aims to evaluate the necessity and effectiveness of using low molecular weight heparin (LMWH) for prophylaxis in the postoperative period in patients who underwent lobectomy due to malignancy, using thromboelastography.Blood samples taken from the patients before low molecular weight heparin prophylaxis (preoperative), before prophylaxis in the postoperative period (postoperative day 1) and after the start of postoperative prophylaxis (postoperative day 3) will be examined by thromboelastography.

Detailed description

General characteristics of the patients such as age, gender, presence of comorbidities, smoking, type of operation and approach applied, operation duration, TEG measurements and postoperative complication development were recorded with case forms.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who underwent lobectomy with thoracotomy or videothoracoscopy (VATS) due to malignancy (primary or secondary lung cancer)

Exclusion criteria

* Patients with a known diagnosis of bleeding or coagulation disorders * Patients receiving anticoagulant and antiplatelet therapy in the preoperative period * Patients who developed perioperative bleeding and therefore underwent perioperative blood and blood product replacement

Design outcomes

Primary

Measure	Time frame	Description
r time	24 months	'r time' value measured by thromboelastography
k time	24 months	'k time' value measured by thromboelastography
maximum amplitude (MA)	24 months	'MA' value measured by thromboelastography
angle a	24 months	'angle a' value measured by thromboelastography

Secondary

Measure	Time frame	Description
complications	24 months	development of complications

Countries

Turkey (Türkiye)

Outcome results